Cardiovascular effects of relaxin: From basic science to clinical therapy

Nature Reviews Cardiology

Volumn 7, Issue 1, 2010, Pages 48-58

  Du, Xiao Jun ^a   Bathgate, Ross A D ^b   Samuel, Chrishan S ^b   Dart, Anthony M ^c   Summers, Roger J ^d  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c MONASH UNIVERSITY   (Australia)

^d MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CYCLIC AMP; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EPLERENONE; GLUCOCORTICOID RECEPTOR; INOTROPIC AGENT; LIGAND; MITOGEN ACTIVATED PROTEIN KINASE; NITRIC OXIDE; PLACEBO; RECEPTOR PROTEIN; RELAXIN; RELAXIN FAMILY PEPTIDE RECEPTOR 1; SPIRONOLACTONE; TYROSINE; UNCLASSIFIED DRUG; VASODILATOR AGENT; VIRUS VECTOR;

ABSENCE OF SIDE EFFECTS; ANGIOGENESIS; BINDING AFFINITY; CARBOXY TERMINAL SEQUENCE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR EFFECT; CLINICAL TRIAL; DISEASE COURSE; DISEASE MARKER; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG TREATMENT FAILURE; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETIC TRANSCRIPTION; GLOMERULUS FILTRATION RATE; HEART FAILURE; HEART MUSCLE FIBROSIS; HEART PROTECTION; HOMEOSTASIS; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MORTALITY; NONHUMAN; NONVIRAL GENE THERAPY; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PLEIOTROPY; POSITIVE FEEDBACK; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN MOTIF; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; REPERFUSION INJURY; REVIEW; SIGNAL TRANSDUCTION; STEM CELL TRANSPLANTATION; VASODILATATION; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; DISEASE MODELS, ANIMAL; FIBROSIS; HEART FAILURE; HUMANS; INFLAMMATION; OXIDATIVE STRESS; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, PEPTIDE; RELAXIN; SIGNAL TRANSDUCTION; VASOCONSTRICTION; VASODILATION;

EID: 76849113368     PISSN: 17595002     EISSN: 17595010     Source Type: Journal    
DOI: 10.1038/nrcardio.2009.198     Document Type: Review

References (115)

1. Sherwood, O. D. Relaxin's physiological roles and other diverse actions. Endocr. Rev. 25, 205-234 (2004).
2. Sherwood, O. D. & O'Byrne, E. M. Purification and characterization of porcine relaxin. Arch. Biochem. Biophys. 160, 185-196 (1974).
3. Hudson, P. et al. Structure of a genomic clone encoding biologically active human relaxin. Nature 301, 628-631 (1983).
4. Hudson, P. et al. Relaxin gene expression in human ovaries and the predicted structure of a human preprorelaxin by analysis of cDNA clones. EMBO J. 3, 2333-2339 (1984).
5. Bathgate, R. A. D., Hsueh, A. J. & Sherwood, O. D. Physiology and molecular biology of the relaxin peptide family in Physiology of Reproduction (eds Knobil, E. & Neill, J. D.) 679-770 (Elsevier, San Diego, 2006).
6. Samuel, C. S., Du, X. J., Bathgate, R. A. D. & Summers, R. J. 'Relaxin' the stiffened heart and arteries: The therapeutic potential for relaxin in the treatment of cardiovascular disease. Pharmacol. Therap. 112, 529-552 (2006).
7. Bani, D. Relaxin: a pleiotropic hormone. Gen. Pharmacol. 28, 13-22 (1997). (Pubitemid 27016053)
8. Samuel, C. S. Relaxin: antifibrotic properties and effects in models of disease. Clin. Med. Res. 3, 241-249 (2005).
9. Lenhart, J. A., Ryan, P. L., Ohleth, K. M., Palmer, S. S. & Bagnell, C. A. Relaxin increases secretion of matrix metalloproteinase-2 and matrix metalloproteinase-9 during uterine and cervical growth and remodeling in the pig. Endocrinology 142, 3941-3949 (2001).
10. Lenhart, J. A., Ryan, P. L., Ohleth, K. M., Palmer, S. S. & Bagnell, C. A. Relaxin increases secretion of tissue inhibitor of matrix metalloproteinase-1 and-2 during uterine and cervical growth and remodeling in the pig. Endocrinology 143, 91-98 (2002).
11. Unemori, E. N. et al. Relaxin stimulates expression of vascular endothelial growth factor in normal human endometrial cells in vitro and is associated with menometrorrhagia in women. Hum. Reprod. 14, 800-806 (1999).
12. Hsu, S. Y. et al. Activation of orphan receptors by the hormone relaxin. Science 295, 671-674 (2002).
13. Bathgate, R. A., Ivell, R., Sanborn, B. M., Sherwood, O. D. & Summers, R. J. International Union of Pharmacology: Recommendations for the nomenclature of receptors for relaxin family peptides. Pharmacol. Rev. 58, 7-31 (2006).
14. Hawkes, C. & Kar, S. The insulin-like growth factor-II/mannose-6- phosphate receptor: structure, distribution and function in the central nervous system. Brain Res. Rev. 44, 117-140 (2004).
15. Pirola, L., Johnston, A. M. & Van Obberghen, E. Modulation of insulin action. Diabetologia 47, 170-184 (2004).
16. De Meyts, P., Palsgaard, J., Sajid, w., Theede, A. M. & Aladdin, H. Structural biology of insulin and IGF-1 receptors. Novartis Found. Symp. 262, 160-171 (2004).
17. Hsu, S. Y. New insights into the evolution of the relaxin-LGR signaling system. Trends Endocrinol. Metab. 14, 303-309 (2003).
18. Bullesbach, E. E. & Schwabe, C. The relaxin receptor-binding site geometry suggests a novel gripping mode of interaction. J. Biol. Chem. 275, 35276-35280 (2000).
19. Bullesbach, E. E. & Schwabe, C. The trap-like relaxin-binding site of the leucine-rich G-protein-coupled receptor 7. J. Biol. Chem. 280, 14051-14056 (2005).
20. Halls, M. L. et al. Multiple binding sites revealed by interaction of relaxin family peptides with native and chimeric relaxin family peptide receptors 1 and 2 (LGR7 and LGR8). J. Pharmacol. Exp. Ther. 313, 677-687 (2005).
21. Sudo, S. et al. H3 relaxin is a specific ligand for LGR7 and activates the receptor by interacting with both the ectodomain and the exoloop 2. J. Biol. Chem. 278, 7855-7862 (2003).
22. Scott, D. J. et al. Characterization of novel splice variants of LGR7 and LGR8 reveals that receptor signaling is mediated by their unique low density lipoprotein class A modules. J. Biol. Chem. 281, 34942-34954 (2006).
23. Scott, D. J. et al. Defining the LGR8 residues involved in binding insulin-like peptide 3. Mol. Endocrinol. 21, 1699-1712 (2007).
24. Hossain, M. A. et al. The A-chain of human relaxin family peptides has distinct roles in the binding and activation of the different relaxin family peptide receptors. J. Biol. Chem. 283, 17287-17297 (2008).
25. Hopkins, E. J., Layfield, S., Ferraro, T., Bathgate, R. A. & Gooley, P. R. The NMR solution structure of the relaxin (RXFP1) receptor lipoprotein receptor class A module and identification of key residues in the N-terminal region of the module that mediate receptor activation. J. Biol. Chem. 282, 4172-4184 (2007).
26. Halls, M. L., Bathgate, R. A. & Summers, R. J. Relaxin family peptide receptors RXFP1 and RXFP2 modulate cAMP signaling by distinct mechanisms. Mol. Pharmacol. 70, 214-226 (2006).
27. Nguyen, B. T., Yang, L., Sanborn, B. M. & Dessauer, C. w. Phosphoinositide 3-kinase activity is required for biphasic stimulation of cyclic adenosine 3′, 5′-monophosphate by relaxin. Mol. Endocrinol. 17, 1075-1084 (2003).
28. Nguyen, B. T. & Dessauer, C. w. Relaxin stimulates protein kinase C translocation: requirement for cyclic adenosine 3′, 5′-monophosphate production. Mol. Endocrinol. 19, 1012-1023 (2005).
29. Halls, M. L. et al. Relaxin family peptide receptor (RXFP1) coupling to Gζi3 involves the C-terminal Arg752 and localization within membrane raft microdomains. Mol. Pharmacol. 75, 415-428 (2009).
30. Kompa, A. R., Samuel, C. S. & Summers, R. J. Inotropic responses to human gene 2 (B29) relaxin in a rat model of myocardial infarction (MI): effect of pertussis toxin. Br. J. Pharmacol. 137, 710-718 (2002).
31. Halls, M. L. et al. RXFP1 couples to the Gα-Gβγ-PI3K- PKCζ pathway via the final 10 amino acids of the receptor C-terminal tail. Ann. N. Y. Acad. Sci. 1160, 117-120 (2009).
32. Ivell, R. & Einspanier, A. Relaxin peptides are new global players. Trends Endocrinol. Metab. 13, 343-348 (2002).
33. Zhang, Q., Liu, S. H., Erikson, M., Lewis, M. & Unemori, E. Relaxin activates the MAP kinase pathway in human endometrial stromal cells. J. Cell. Biochem. 85, 536-544 (2002).
34. Moore, X. L. et al. Relaxin antagonizes hypertrophy and apoptosis in neonatal rat cardiomyocytes. Endocrinology 148, 1582-1589 (2007).
35. Palejwala, S., Stein, D., wojtczuk, A., weiss, G. & Goldsmith, L. T. Demonstration of a relaxin receptor and relaxin-stimulated tyrosine phosphorylation in human lower uterine segment fibroblasts. Endocrinology 139, 1208-1212 (1998).
36. Conrad, K. P. & Novak, J. Emerging role of relaxin in renal and cardiovascular function. Am. J. Physiol. Regul. Integr. Comp. Physiol. 287, R250-R261 (2004).
37. Cosen-Binker, L. I., Binker, M. G., Cosen, R., Negri, G. & Tiscornia, O. Relaxin prevents the development of severe acute pancreatitis. World J. Gastroenterol. 12, 1558-1568 (2006).
38. Masini, E. et al. Protective effects of relaxin in ischemia/reperfusion- induced intestinal injury due to splanchnic artery occlusion. Br. J. Pharmacol. 148, 1124-1132 (2006).
39. Zhang, J. et al. Effect of relaxin on myocardial ischemia injury induced by isoproterenol. Peptides 26, 1632-1639 (2005).
40. Boehnert, M. U., Hilbig, H. & Armbruster, F. P. Relaxin as an additional protective substance in preserving and reperfusion solution for liver transplantation, shown in a model of isolated perfused rat liver. Ann. N. Y. Acad. Sci. 1041, 434-440 (2005).
41. Perna, A. M. et al. Novel drug development opportunity for relaxin in acute myocardial infarction: evidences from a swine model. FASEB J. 19, 1525-1527 (2005).
42. Bani, D., Masini, E., Bello, M. G., Bigazzi, M. & Sacchi, T. B. Relaxin protects against myocardial injury caused by ischemia and reperfusion in rat heart. Am. J. Pathol. 152, 1367-1376 (1998).
43. Nistri, S., Chiappini, L., Sassoli, C. & Bani, D. Relaxin inhibits lipopolysaccharide-induced adhesion of neutrophils to coronary endothelial cells by a nitric oxide-mediated mechanism. FASEB J. 17, 2109-2111 (2003).
44. Failli, P. et al. Relaxin up-regulates inducible nitric oxide synthase expression and nitric oxide generation in rat coronary endothelial cells. FASEB J. 16, 252-254 (2002).
45. Masini, E. et al. Relaxin counteracts myocardial damage induced by ischemia-reperfusion in isolated guinea pig hearts: evidence for an involvement of nitric oxide. Endocrinology 138, 4713-4720 (1997).
46. Bani-Sacchi, T., Bigazzi, M., Bani, D., Mannaioni, P. F. & Masini, E. Relaxin-induced increased coronary flow through stimulation of nitric oxide production. Br. J. Pharmacol. 116, 1589-1594 (1995).
47. Masini, E. et al. Protective effect of relaxin in cardiac anaphylaxis: involvement of the nitric oxide pathway. Br. J. Pharmacol. 137, 337-344 (2002).
48. Wilson, B. C., Connell, B. & Saleh, T. M. Relaxin-induced reduction of infarct size in male rats receiving MCAO is dependent on nitric oxide synthesis and not estrogenic mechanisms. Neurosci. Lett. 393, 160-164 (2006).
49. Dschietzig, T. et al. Relaxin, a pregnancy hormone, is a functional endothelin-1 antagonist: attenuation of endothelin-1-mediated vasoconstriction by stimulation of endothelin type-B receptor expression via ERK-1/2 and nuclear factor-κB. Circ. Res. 92, 32-40 (2003).
50. Kerchner, L. J. et al. Evidence against the hypothesis that endothelial endothelin B receptor expression is regulated by relaxin and pregnancy. Endocrinology 146, 2791-2797 (2005).
51. Dschietzig, T., Bartsch, C., Stangl, V., Baumann, G. & Stangl, K. Identification of the pregnancy hormone relaxin as glucocorticoid receptor agonist. FASEB J. 18, 1536-1538 (2004).
52. Dschietzig, T., Bartsch, C., Baumann, G. & Stangl, K. RXFP1-inactive relaxin activates human glucocorticoid receptor: further investigations into the relaxin-GR pathway. Regul. Pept. 154, 77-84 (2009).
53. Dschietzig, T., Bartsch, C., Baumann, G. & Stangl, K. Relaxin-a pleiotropic hormone and its emerging role for experimental and clinical therapeutics. Pharmacol. Therap. 112, 38-56 (2006).
54. Jeyabalan, A., Shroff, S. G., Novak, J. & Conrad, K. P. The vascular actions of relaxin. Adv. Exp. Med. Biol. 612, 65-87 (2007).
55. Fisher, C. et al. Is the pregnancy hormone relaxin also a vasodilator peptide secreted by the heart? Circulation 106, 292-295 (2002).
56. Debrah, D. O., Conrad, K. P., Jeyabalan, A., Danielson, L. A. & Shroff, S. G. Relaxin increases cardiac output and reduces systemic arterial load in hypertensive rats. Hypertension 46, 745-750 (2005).
57. Tozzi, C. A. et al. Recombinant human relaxin reduces hypoxic pulmonary hypertension in the rat. Pulm. Pharmacol. Ther. 18, 346-353 (2005).
58. St-Louis, J. & Massicotte, G. Chronic decrease of blood pressure by rat relaxin in spontaneously hypertensive rats. Life Sci. 37, 1351-1357 (1985).
59. Conrad, K. P. Mechanisms of renal vasodilation and hyperfiltration during pregnancy. J. Soc. Gynecol. Investig. 11, 438-448 (2004).
60. Jeyabalan, A. & Conrad, K. P. Renal function during normal pregnancy and preeclampsia. Front. Biosci. 12, 2425-2437 (2007).
61. Debrah, D. O., Conrad, K. P., Danielson, L. A. & Shroff, S. G. Effects of relaxin on systemic arterial hemodynamics and mechanical properties in conscious rats: Sex dependency and dose response. J. Appl. Physiol. 98, 1013-1020 (2005).
62. Dschietzig, T. et al. Intravenous recombinant human relaxin in compensated heart failure: a safety, tolerability, and pharmacodynamic trial. J. Card. Fail. 15, 182-190 (2009).
63. Teerlink, J. R. et al. Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study. Lancet 373, 1429-1439 (2009).
64. Unemori, E. N. et al. Relaxin induces vascular endothelial growth factor expression and angiogenesis selectively at wound sites. Wound Repair. Regen. 8, 361-370 (2000).
65. Formigli, L. et al. Paracrine effects of transplanted myoblasts and relaxin on postinfarction heart remodelling. J. Cell. Mol. Med. 11, 1087-1100 (2007).
66. Coulson, C. C., Thorp, J. M., Jr, Mayer, D. C. & Cefalo, R. C. Central hemodynamic effects of recombinant human relaxin in the isolated, perfused rat heart model. Obstet. Gynecol. 87, 610-612 (1996).
67. Toth, M., Taskinen, P. & Ruskoaho, H. Relaxin stimulates atrial natriuretic peptide secretion in perfused rat heart. J. Endocrinol. 150, 487-495 (1996).
68. Kakouris, H., Eddie, L. w. & Summers, R. J. Cardiac effects of relaxin in rats. Lancet 339, 1076-1078 (1992).
69. ward, D. G., Thomas, G. R. & Cronin, M. J. Relaxin increases rat heart rate by a direct action on the cardiac atrium. Biochem. Biophys. Res. Commun. 186, 999-1005 (1992).
70. Tan, Y. Y., wade, J. D., Tregear, G. w. & Summers, R. J. Comparison of relaxin receptors in rat isolated atria and uterus by use of synthetic and native relaxin analogues. Br. J. Pharmacol. 123, 762-770 (1998).
71. Tan, Y. Y., wade, J. D., Tregear, G. w. & Summers, R. J. Quantitative autoradiographic studies of relaxin binding in rat atria, uterus and cerebral cortex: characterization and effects of oestrogen treatment. Br. J. Pharmacol. 127, 91-98 (1999).
72. Bathgate, R. A. D. et al. The Relaxin-Like Factor (Insulin 3) is highly expressed in the ruminant ovary: A putative ruminant relaxin? in Relaxin 2000: Proceedings of the Third International Conference on Relaxin and Related Peptides (eds. Tregear, G. w., Ivell, R., Bathgate, R. A. & wade, J. D.) 349-356 (Kluwer, Dordrecht, 2001).
73. Samuel, C. S. et al. Relaxin modulates cardiac fibroblast proliferation, differentiation and collagen production and reverses cardiac fibrosis in vivo. Endocrinology 145, 4125-4133 (2004).
74. Lekgabe, E. D. et al. Relaxin reverses cardiac and renal fibrosis in spontaneously hypertensive rats. Hypertension 46, 412-418 (2005).
75. Samuel, C. S., Hewitson, T. D., Zhang, Y. & Kelly, D. J. Relaxin ameliorates fibrosis in experimental diabetic cardiomyopathy. Endocrinology 149, 3286-3293 (2008).
76. Bathgate, R. A. et al. Adenovirus-mediated delivery of relaxin reverses cardiac fibrosis. Mol. Cell. Endocrinol. 280, 30-38 (2008).
77. Bonacchi, M. et al. Functional and histopathological improvement of the postinfarcted rat heart upon myoblast cell grafting and relaxin therapy. J. Cell. Mol. Med. doi: 10.1111/j.1582-4934.2008.00503.x
78. Du, X. J. et al. Increased myocardial collagen and ventricular diastolic dysfunction in relaxin deficient mice: a gender-specific phenotype. Cardiovasc. Res. 57, 395-404 (2003).
79. Du, X. J. et al. Reversal of cardiac fibrosis and related dysfunction by relaxin. Ann. N. Y. Acad. Sci. 1160, 278-284 (2009).
80. Laflamme, M. A. & Murry, C. E. Regenerating the heart. Nat. Biotechnol. 23, 845-856 (2005).
81. Formigli, L. et al. Morphofunctional integration between skeletal myoblasts and adult cardiomyocytes in coculture is favored by direct cell-cell contacts and relaxin treatment. Am. J. Physiol. Cell Physiol. 288, C795-C804 (2005).
82. Formigli, L. et al. Skeletal myoblasts overexpressing relaxin improve differentiation and communication of primary murine cardiomyocyte cell cultures. J. Mol. Cell. Cardiol. 47, 335-345 (2009).
83. Dschietzig, T. et al. The pregnancy hormone relaxin is a player in human heart failure. FASEB J. 15, 2187-2195 (2001).
84. Xu, Q. et al. Endogenous relaxin does not affect chronic pressure overload-induced cardiac hypertrophy and fibrosis. Endocrinology 149, 476-482 (2008).
85. Fisher, C., Berry, C., Blue, L., Morton, J. J. & McMurray, J. N-terminal pro B type natriuretic peptide, but not the new putative cardiac hormone relaxin, predicts prognosis in patients with chronic heart failure. Heart 89, 879-881 (2003).
86. Hocher, B. et al. Relaxin is an independent risk factor predicting death in male patients with end-stage kidney disease. Circulation 109, 2266-2268 (2004).
87. Kupari, M., Mikkola, T. S., Turto, H. & Lommi, J. Is the pregnancy hormone relaxin an important player in human heart failure? Eur. J. Heart Fail. 7, 195-198 (2005).
88. Gedikli, O. et al. Circulating levels of relaxin and its relation to cardiovascular function in patients with hypertension. Blood Press. 18, 68-73 (2009).
89. Giordano, N. et al. Serum relaxin in systemic sclerosis. J. Rheumatol. 32, 2164-2166 (2005).
90. Stewart, D. R. et al. The relationship between hCG and relaxin secretion in normal pregnancies vs peri-implantation spontaneous abortions. Clin. Endocrinol. 38, 379-385 (1993).
91. Cossum, P. A. et al. The disposition of a human relaxin (hRlx-2) in pregnant and nonpregnant rats. Pharm. Res. 9, 419-424 (1992).
92. Smith, M. C. et al. Influence of recombinant human relaxin on renal hemodynamics in healthy volunteers. J. Am. Soc. Nephrol. 17, 3192-3197 (2006).
93. Teichman, S. L. et al. Relaxin, a pleiotropic vasodilator for the treatment of heart failure. Heart Fail. Rev. doi:10.1007/s10741-008-9129-3
94. Iles, L. et al. Evaluation of diffuse myocardial fibrosis in heart failure with cardiac magnetic resonance contrast-enhanced T1 mapping. J. Am. Coll. Cardiol. 52, 1574-1580 (2008).
95. Miragoli, M., Salvarani, N. & Rohr, S. Myofibroblasts induce ectopic activity in cardiac tissue. Circ. Res. 101, 755-758 (2007).
96. Burstein, B. & Nattel, S. Atrial fibrosis: mechanisms and clinical relevance in atrial fibrillation. J. Am. Coll. Cardiol. 51, 802-809 (2008).
97. Pitt, B. et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N. Engl. J. Med. 341, 709-717 (1999).
98. Pitt, B. et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N. Engl. J. Med. 348, 1309-1321 (2003).
99. Ouvrard-Pascaud, A. et al. Conditional mineralocorticoid receptor expression in the heart leads to life-threatening arrhythmias. Circulation 111, 3025-3033 (2005).
100. Tabanelli, S., Tang, B. & Gurpide, E. In vitro decidualization of human endometrial stromal cells. J. Steroid Biochem. Mol. Biol. 42, 337-344 (1992).
101. Halls, M. L. et al. Relaxin activates multiple cAMP signaling pathway profiles in different target cells. Ann. N. Y. Acad. Sci. 1160, 108-111 (2009).
102. Quattrone, S., Chiappini, L., Scapagnini, G., Bigazzi, B. & Bani, D. Relaxin potentiates the expression of inducible nitric oxide synthase by endothelial cells from human umbilical vein in in vitro culture. Mol. Hum. Reprod. 10, 325-330 (2004).
103. Bani, D. et al. Relaxin activates the l-arginine-nitric oxide pathway in vascular smooth muscle cells in culture. Hypertension 31, 1240-1247 (1998).
104. Debrah, D. O. et al. Relaxin is essential for systemic vasodilation and increased global arterial compliance during early pregnancy in conscious rats. Endocrinology 147, 5126-5131 (2006).
105. Erikson, M. S. & Unemori, E. N. Relaxin clinical trials in systemic sclerosis. in Relaxin 2000: Proceedings of the Third International Conference on Relaxin and Related Peptides (eds Tregear, G. w., Ivell, R., Bathgate, R. A. & wade, J. D.) 373-382 (Kluwer, Amsterdam, 2001).
106. Smith, M. C., Danielson, L. A., Conrad, K. P. & Davison, J. M. Influence of recombinant human relaxin on renal hemodynamics in healthy volunteers. J. Am. Soc. Nephrol. 17, 3192-3197 (2006).
107. Halls, M. L., van der westhuizen, E. T., Bathgate, R. A. & Summers, R. J. Relaxin family peptide receptors-former orphans reunite with their parent ligands to activate multiple signalling pathways. Br. J. Pharmacol. 150, 677-691 (2007).
108. Danielson, L. A. & Conrad, K. P. Time course and dose response of relaxin-mediated renal vasodilation, hyperfiltration, and changes in plasma osmolality in conscious rats. J. Appl. Physiol. 95, 1509-1514 (2003).
109. Unemori, E. N. & Amento, E. P. Relaxin modulates synthesis and secretion of procollagenase and collagen by human dermal fibroblasts. J. Biol. Chem. 265, 10681-10685 (1990).
110. Callander, G. E., Thomas, w. G. & Bathgate, R. A. Prolonged RXFP1 and RXFP2 signaling can be explained by poor internalization and a lack of β-arrestin recruitment. Am. J. Physiol. Cell. Physiol. 296, C1058-C1066 (2009).
111. De Meyts, P. et al. Structural basis of allosteric ligand-receptor interactions in the insulin/relaxin peptide family: implications for other receptor tyrosine kinases and G-protein-coupled receptors. Ann. N. Y. Acad. Sci. 1160, 45-53 (2009).
112. Svendsen, A. M. et al. Dimerization and negative cooperativity in the relaxin family peptide receptors. Ann. N. Y. Acad. Sci. 1160, 54-59 (2009).
113. Svendsen, A. M. et al. Negative cooperativity in H2 relaxin binding to a dimeric relaxin family peptide receptor 1. Mol. Cell. Endocrinol. 296, 10-17 (2008).
114. Osheroff, P. L., Cronin, M. J. & Lofgren, J. A. Relaxin binding in the rat heart atrium. Proc. Natl Acad. Sci. USA 89, 2384-2388 (1992).
115. Dschietzig, T., Bartsch, C., Stangl, V., Baumann, G. & Stangl, K. Myocardial relaxin counteracts hypertrophy in hypertensive rats. Ann. N. Y. Acad. Sci. 1041, 441-443 (2005).